Cited by 1,284Telomeres, Telomerase, and SenescenceGenetics, Aging, and Longevity in Model OrganismsSirtuins and Resveratrol in Medicine

Senescent cells: an emerging target for diseases of ageing

Open access
Childs, Bennett G., Gluscevic, Martina, Baker, Darren J., Laberge, Remi-Martin, Marquess, Dan, Dananberg, Jamie, van Deursen, Jan M.·2017·Nature Reviews Drug Discovery

Abstract

Chronological age represents the single greatest risk factor for human disease. One plausible explanation for this correlation is that mechanisms that drive ageing might also promote age-related diseases. Cellular senescence, which is a permanent state of cell cycle arrest induced by cellular stress, has recently emerged as a fundamental ageing mechanism that also contributes to diseases of late life, including cancer, atherosclerosis and osteoarthritis. Therapeutic strategies that safely interfere with the detrimental effects of cellular senescence, such as the selective elimination of senescent cells (SNCs) or the disruption of the SNC secretome, are gaining significant attention, with several programmes now nearing human clinical studies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nrd.2017.116

Cites

217 of 217 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In cancer, the SASP can frequently promote therapy resistance and recurrence.

    “In cancer, the SASP can frequently promote therapy resistance and recurrence [34].”

    From The role of cellular senescence and SASP in tumour microenvironment (2023) · cites this paper as [34]

    In “SASP neutralization” (page not provided), the paper says that suppressing the SASP in a mouse lymphoma model blunts immune surveillance and drives treatment resistance and relapse—the opposite direction from the claim. “SNCs possess a bioactive secretome” describes the SASP as potentially tumour-promoting, but does not say it frequently promotes therapy resistance or recurrence. (LLM, conf=0.85)

    Checked by a reasoning model — may be wrong.

    Experimental — accuracy not yet measured
  • Senescent cells accumulate in most tissues with age and are important components of the overall aging process.

    “While senescence has beneficial functions (such as tumor suppression), senescent cells accumulate in most tissues with age, and they are important components of the overall aging process62.”

    From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [62]

    The Abstract says senescent cells accumulate over time and are directly linked to features of natural ageing. The Discovery and detection of SNCs section describes them in numerous aged rodent and primate tissues, but the passages do not establish the stronger claim that they accumulate in most tissues. (LLM, conf=0.83)

    Experimental — accuracy not yet measured
  • Several senolytic drugs, such as ABT-737, BET inhibitors and dasatinib plus quercetin, can selectively induce cell death in senescent cells and effectively improve some symptoms of age-related disease, including cancer, by attenuating SASP factor production.

    “Several senolytic drugs, such as ABT‐737, BET inhibitors and dasatinib plus quercetin, can selectively induce cell death in senescent cells and effectively improve some symptoms of age‐related disease, including cancer, by attenuating SASP factor production.81”

    From Cellular senescence and senescence-associated secretory phenotype via the cGAS-STING signaling pathway in cancer (2020) · cites this paper as [81]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • Senescent cells build up in many diseases associated with ageing.

    “The literature is becoming inundated with evidence that senescent cells accumulate in a variety of age-associated diseases13.”
  • Failsafe cellular senescence occurs in response to oncogene activation, oncosuppressor inactivation, and sublethal insults including telomere shortening, DNA damage, mitochondrial dysfunction, defective/stalled DNA replication, and epigenetic, lysosomal, mechanical, metabolic, mitotic, oxidative, or proteotoxic challenges.

    “In particular, this failsafe cellular senescence reportedly occurs in response to (1) potentially carcinogenic events including oncogene activation or oncosuppressor gene inactivation; and (2) several sublethal cellular insults, including telomere shortening, DNA damage, mitochondrial dysfunction, defective/stalled DNA replication and epigenetic, lysosomal, mechanical, metabolic, mitotic, ox”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Childs, B. G., Gluscevic, M., Baker, D. J., Laberge, R.-M., Marquess, D., Dananberg, J., & van Deursen, J. M.
Affiliations
  • Mayo Clinic (US)
  • Unity Biotechnology (United States) (US)
Venue
Nature Reviews Drug Discovery
Published
2017-07-21
Volume
16
Issue
10
Pages
718-735
ISSN
  • 1474-1776 (ISSN-L)
  • 1474-1784
OpenAlex
W2739438570
Cited by
1,284
References
216
Citations by year
2026: 146 · 2025: 157 · 2024: 166 · 2023: 162 · 2022: 149 · 2021: 168 · 2020: 146 · 2019: 108 · 2018: 73 · 2017: 8 · 2013: 1
FWCI
11.24
Type
journal article
Language
en
Open access
Locations
  • Nature Reviews Drug Discovery (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
Funders
  • National Institute on Aging (T32AG049672)
  • National Cancer Institute (R01CA168709, R01CA096985)
Topics
  • Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
  • Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
Keywords
cellular senescence, senescent cells, aging, age-related diseases, cancer, atherosclerosis, osteoarthritis, senolytics, senescence-associated secretory phenotype, cell cycle arrest, cellular stress, senolytic therapy
MeSH terms
Aging, Animals, Humans, Neoplasms, Cellular Senescence, Cell Proliferation, Atherosclerosis, Cell Cycle Checkpoints

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review